New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For BMY;VNO;JCP;CAT;STRA;PBR;GRMN;KRC;IQNT;JNJ;VRTX;NKTR;HES From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
January 20, 2015
09:21 EDTJNJJ&J says negative impact of currency to be 'more significant' than expected
Says currency impact will be more significant in 1H than in 2H.
09:20 EDTJNJJ&J says 'comfortable' with models reflecting midpoint of FY EPS view
Subscribe for More Information
09:18 EDTJNJJohnson & Johnson sees FY15 reported sales $75B-$76B
Subscribe for More Information
09:18 EDTJNJJohnson & Johnson CEO says core businesses 'strong'
Johnson & Johnson (JNJ) providing sustainable, high quality healthcare "one of society's greatest challenges." Says core businesses "strong," positioned to continue expanding their leadership positions. CEO Alex Gorsky says company is changing the way it interacts with customers, evolving to be more "effective," "efficient." Says U.S. OTC consent decree requirements completed. Says in the process of developing a China lung center. Says still plans to take $1B out of P&L in next three years. Says aims to bring Ebola vaccine to market "as fast as possible." Says "well-positioned" for long-term. Says currency headwinds have increased "quite substantially," negatively impacting sales, earnings to greater extent than company had anticipated. Sees Depomed (DEPO) transaction closing in Q2. Expects R&D tax credit will be renewed in 2015. If R&D tax credit is approved, sees effective tax rate for 2015 of approx. 20%-21%. Sees operational sales growth for 2015 approx. 6%. Says Wall Street forecasts may not adequately reflect likely negative impact in 2015 of foreign exchange. Sees FY15 operational sales growth 1%-2% in constant currency. Comments made on the Q4 earnings conference call.
08:18 EDTJNJJohnson & Johnson sees 10 major Pharmaceuticals filings from 2013-2017
Sees 10 major filings, 25 line extensions in Pharmaceuticals expected between 2013-2017. Sees about 100 ongoing discovery projects, 50 novel compounds in early development, 5 breakthrough designations. Sees 30 major Medical Devices filings expected from 2014-2016, 20 key Consumer product launches expected global in 2015. Says near-term priorities include: Accelerating growth in Medical Devices through innovation, expanding market leadership in key consumer segments like OTC, Oral Care, Baby and Beauty. Comments from slides that will be presented on the Q4 earnings conference call.
07:52 EDTJNJJohnson & Johnson reports Q4 Pharmaceutical sales $8B
Subscribe for More Information
07:48 EDTJNJJohnson & Johnson sees FY15 adjusted EPS $6.12-$6.27, consensus $6.13
Subscribe for More Information
07:46 EDTJNJJohnson & Johnson reports Q4 EPS ex-items $1.27, consensus $1.26
Subscribe for More Information
06:22 EDTJCPJ.C. Penney to bring back 120-page catalog, WSJ reports
J.C. Penney has decided to resurrect its catalog in the form of a 120-page book that will mark the first catalog the chain has sent out since 2010, The Wall Street Journal reports. The retailer, which quit the catalog amid a broader pullback caused by the recession and the rise of e-commerce, now believes the catalog can help drive web sales. Reference Link
January 16, 2015
16:29 EDTJNJOn The Fly: Closing Wrap
Subscribe for More Information
16:07 EDTIQNTInteliquent CEO Edward Evans to depart company
Inteliquent announced that G. Edward Evans will be departing as the company's CEO in order to pursue other interests. Evans' employment agreement is set to expire on March 31. However, the company and Evans anticipate that Evans will continue to act as the company's CEO beyond such date if necessary to permit the company to complete a nationwide search for his successor. In addition, it is anticipated that Evans will resign as a member of the company's board upon his departure as CEO.
16:00 EDTPBROptions Update; January 16, 2015
Subscribe for More Information
13:01 EDTJNJEarnings Preview: Johnson & Johnson reports after recent Goldman downgrade
Subscribe for More Information
12:43 EDTJNJOn The Fly: Midday Wrap
Subscribe for More Information
10:13 EDTVNOBofA/Merrill Office REITs analyst holds analyst/industry conference call
U.S. Office & Warehouse REIT Analyst Feldman, along with Jones Lang LaSalle (JLL) Research, Lasing and Capital Markets teams, provide a comprehensive update on leasing and capital market conditions ahead of earnings on an Analyst/Industry conference call to be held on January 20 at 11 am.
08:58 EDTJNJRoth Capital says Depomed now leading pain company, ups to Buy
Roth Capital upgraded Depomed (DEPO) to Buy from Neutral saying the Nucynta transaction transforms the company into a "leading pain company now with critical mass." Roth raised its price target for shares to $25. Depomed last night announced that it acquired the U.S. rights to the Nucyntafranchise for $1.05B from Johnson & Johnson's (JNJ) Jansen unit. Depomed is trading up 9% in pre-market trading to $19.19.
08:12 EDTJNJJohnson & Johnson forms Ebola vaccine development consortia
Subscribe for More Information
07:23 EDTCATJim Chanos says long shares of Apple
Subscribe for More Information
07:16 EDTCATCaterpillar January weekly volatility elevated into Q4 and outlook
Subscribe for More Information
07:12 EDTCATChanos says two of three Caterpillar areas 'highly troubled'
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use